Robert Driscoll
Stock Analyst at Wedbush
(0)
# 4588
Out of 5,270 analysts
197
Total ratings
21.90%
Success rate
-15.93%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Day One Biopharmaceu... | Reiterates: Outperform | 32 32 | 8.53 | 275.15% | 6 | Feb 26, 2025 | |
Kura Oncology | Maintains: Outperform | 34 36 | 7.37 | 388.47% | 8 | Feb 6, 2025 | |
IDEAYA Biosciences | Reiterates: Outperform | 52 52 | 19.56 | 165.85% | 9 | Dec 17, 2024 | |
Revolution Medicines | Maintains: Outperform | 70 67 | 38.55 | 73.8% | 4 | Dec 6, 2024 | |
Tyra Biosciences | Reiterates: Outperform | 28 28 | 11.35 | 146.7% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 16 16 | 1.92 | 733.33% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 30 30 | 10.46 | 186.81% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 25 22 | 1.26 | 1646.03% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 85 51 | 6.85 | 644.53% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 5 5 | 0.86 | 481.4% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 36 36 | 8.32 | 332.69% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 11 11 | 5.47 | 101.1% | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 11 11 | 2.54 | 333.07% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 4 | 1.93 | 107.25% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 13 13 | 4.3 | 202.33% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 13 | 1.88 | 591.49% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 74 74 | 31.8 | 132.7% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 12 12 | n/a | n/a | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 8 8 | 2.66 | 200.75% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 57 57 | 16.51 | 245.25% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 7 7 | 1.75 | 300% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 65 | n/a | n/a | 8 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 3 8 | 0.65 | 1130.77% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 8 8 | 0.48 | 1566.67% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 52 | 12.11 | 329.4% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 9 | 1.17 | 669.23% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 4 1 | n/a | n/a | 4 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 3 | n/a | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 36 | n/a | n/a | 2 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 50 70 | n/a | n/a | 4 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 9 2 | n/a | n/a | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 136 17 | n/a | n/a | 3 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 5 9 | n/a | n/a | 6 | Jun 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 2 4 | 3.46 | 15.61% | 4 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 1500 250 | n/a | n/a | 1 | Mar 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 3 | n/a | n/a | 3 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 30 34 | n/a | n/a | 1 | Apr 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 120 160 | n/a | n/a | 1 | Feb 22, 2017 |